发明名称 HDAC inhibitors and therapeutic methods using the same
摘要 Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
申请公布号 US9249087(B2) 申请公布日期 2016.02.02
申请号 US201213985760 申请日期 2012.01.31
申请人 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS;THE CHILDREN'S HOSPITAL OF PHILADELPHIA 发明人 Kozikowski Alan;Kalin Jay H.;Butler Kyle V.;Bergman Joel;Hancock Wayne W.
分类号 A61K31/497;A61K31/405;C07D209/04;C07D207/30;C07C229/52;A61K51/04;C07C259/10;C07D207/323;C07D209/08;C07D209/14;C07D213/56;C07D231/12;C07D235/06;C07D473/00;A61K49/00 主分类号 A61K31/497
代理机构 Marshall, Gerstein & Borun LLP 代理人 Marshall, Gerstein & Borun LLP
主权项 1. A compound having a structural formula Cap-L-M wherein Cap is selected from the group consisting of wherein ring  is an aliphatic or aromatic five or six membered ring, W, X, Y, and Z independently are selected from the group consisting of null, C(R1)2, O, S, and NR1, ring  is an aliphatic or aromatic six membered ring, wherein D, E, F, and G independently are selected from the group consisting of C(R1)2, O, and S, or ring  is an aliphatic or aromatic five membered ring, wherein D, E, F, and G are selected from the group consisting of null, C(R1)2, and NR1, R1, independently, is selected from the group consisting of null, hydrogen, C1-6alkyl, C1-6heteroalkyl, C2-6alkenyl, C1-6perfluoroalkyl, C1-6perfluoroalkoxy, aryl, heteroaryl, C3-10cycloalkyl, C3-10heterocycloalkyl, C1-6alkylenearyl, C1-6alkyleneheteroaryl, C1-6alkyleneheterocycloalkyl, C1-6alkylenecycloalkyl,  ORa, halo, N(Ra)2, SRa, SORa, SO2Ra, CN, C(═O)Ra, CF3, OCF3, NO2, OC(═O)Ra, SO2N(Ra)2, OSO2CF3, C(═O)ORa, C(═O)N(Ra)2, C1-6alkyleneN(Ra)2, C1-6alkyleneC(═O)Ra, C1-6alkyleneORa, C1-6alkyleneSRa, C1-6alkyleneNRaSO2Ra, C1-6alkyleneSORa, C1-6alkyleneCN, C1-6heteroalkyleneCN, C1-6alkyleneC(═O)ORa, C1-6alkyleneOC(═O)N(Ra)2, C1-6alkyleneNRaC(═O)ORa, C1-6alkyleneNRaC(═O)Ra, C1-6alkylene C(═O)N(Ra)2, C1-6alkyleneOC1-6alkyleneC(═O)ORa, C(═O)NRaSO2Ra, C(═O)C1-6alkylenearyl, C(═O)NRaC1-6alkyleneORa, OC1-6alkyleneC(═O)ORa, OC1-6alkyleneN(Ra)2, OC1-6alkyleneORa, OC1-6alkyleneNRaC(═O)ORa, NRaC1-6alkyleneN(Ra)2, NRaC(═O)Ra, NRaC(═O)N(Ra)2, N(SO2C1-6alkyl)2, and NRa(SO2C1-6alkyl), and Ra, independently, is selected from the group consisting of hydrogen, C1-6alkyl, C1-6heteroalkyl, C1-6alkyleneNH2, C1-6alkyleneNH(C1-6alkyl), C1-6alkyleneN(C1-6alkyl)2, C1-6alkyleneNH(C1-6alkyl)2, C1-6alkyleneNHC(═O)(C1-6alkyl), C1-6alkyleneC(═O)NH2, C1-6alkyleneOH, C1-6alkyleneCN, C1-6heteroalkyleneCN, C1-6alkyleneOC1-6alkyl, C1-6alkyleneSH, C1-6alkyleneSC1-6alkyl, C1-6alkyleneNH(SO2C1-6alkyl), aryl, heteroaryl, C3-8cycloalkyl, and C3-10heterocycloalkyl, wherein linker L is attached to any atom D, E, F, or G, wherein ring  is an aliphatic or aromatic five or six membered ring, E, F, W, X, Y, Z, R1, and Ra are as defined above, and wherein A is C, N, O, S, B, or P, and L is attached to A, R2, R3 and R4 independently are selected from the group consisting of null, hydrogen, C1-6alkyl, C1-6heteroalkyl, C2-6alkenyl, C1-6perfluoroalkyl, C1-6perfluoroalkoxy, aryl, heteroaryl, C3-10cycloalkyl, C3-8heterocycloalkyl, C1-6alkylenearyl, C1-6alkyleneheteroaryl, C1-6alkyleneheterocycloalkyl, C1-6alkylenecycloalkyl,  ORa, halo, N(Ra)2, SRa, SORa, SO2Ra, CN, C(═O)Ra, OC(═O)Ra, C(═O)ORa, C1-6alkyleneN(Ra)2, C1-6alkyleneORa, C1-6alkyleneSRa, C1-6alkyleneC(═O)ORa, C(═O)N(Ra)2, C(═O)NRaC1-6alkyleneORa, OC1-6alkyleneC(═O)ORa, OC1-6alkyleneN(Ra)2, OC1-6alkyleneORa, OC1-6alkyleneNRaC(═O)ORa, NRaC1-6alkyleneN(Ra)2, NRaC(═O)Ra, NRaC(═O)N(Ra)2, N(SO2C1-6alkyl)2, NRa(SO2C1-6alkyl), nitro, and SO2N(Ra)2, and Ra is defined above; L is selected from the group consisting of null, C1-8alkylene, Ra substituted C1-8alkylene, NRa, C(═O), aryl, C(═O)aryl, C(═O)C1-6alkylene, C1-8alkyleneNRa, C1-6alkylenearyleneC1-6alkylene, C2-6alkenylene, C4-8alkdienylene, C1-6alkylenearylene, C1-6alkyleneheteroarylene, Ra substituted C1-6alkyleneheteroarylene, and C2-6alkenylenearyleneC1-6alkylene, and Ra is defined above; M is selected from the group consisting of —C(═O)N(Rb)OH, —O(CH2)1-6C(═O)N(Rb)ORb, —N(Rb)(CH2)1-6C(═O)N(Rb)ORb, —N(Rb)(CH2)1-6C(═O)N(Rb)ORb, arylC(═O)NHOH, —N(OH)C(═O)Rb, heteroarylC(═O)NHOH, —C3-6cycloalkylN—C(═O)CH2SH, —B(ORb)2, —SO2NHRb, —NHSO2NHRb, —NHSO2C1-6alkyl, —SO2C1-6alkyl, —SRc, —C(═O)Re, —P(═O)(ORf)2, —NH—P(═O)(ORf)2, —C(═O)(C(Rb)2)1-6SH, —C(═O)C(═O)NHRb, —C(═O)NHN(Rb)2, —C(═O)NH(CH2)1-3N(Rb)2, —S—(C═O)C1-6alkyl, C3-10heterocycloalkyl optionally substituted with oxo (═O), thioxo (═S), or both, aryl optionally substituted with one or more of C1-6alkyl, —C(═O)Rd, —NH2, and —SH, heteroaryl optionally substituted with —NH2, —SH, or both, —N(H)C(═O)SH, —NHC(═O)NHRd, —NHC(═O)CH2Rd, —NHC(═O)(CH2)1-6SH, —NHC(═O)CH2Hal, —NHC(═S)NHRd, —NHC(═S)CH2Rd, —C(═S)NHRd, —C(═S)CH2Rd, —NHC(═S)CH2Rd, —NHC(═S)CH2Hal, and —(C═O)C1-6alkyl; Rb, independently, is selected from the group consisting of hydrogen, (C═O)CH3, C1-6alkyl, CF3, CH2F, and aryl, or two Rb groups are taken together with the carbon to which they attached to form a C3-8cycloalkyl group; Rc is selected from hydrogen or (C═O)CH3; Rd is NH2 or OH; Re is selected from the group consisting of OH, N(Rb)2, NH(OCH3), N(CH3)OH, C1-6alkyl, CF3, aryl, heteroaryl, C3-8cycloalkyl, NHSO2CH3, NHSO2CF3, and C1-6haloalkyl; Rf independently is hydrogen, methyl, or ethyl; and Hal is halo, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof.
地址 Urbana IL US